Oramed Pharmaceuticals Inc. (ORMP)
NASDAQ: ORMP · Real-Time Price · USD
3.880
+0.020 (0.52%)
At close: Apr 17, 2026, 4:00 PM EDT
3.853
-0.027 (-0.71%)
After-hours: Apr 17, 2026, 7:41 PM EDT
Oramed Pharmaceuticals Revenue
In the year 2025, Oramed Pharmaceuticals had annual revenue of $2.00M.
Revenue (ttm)
$2.00M
Revenue Growth
n/a
P/S Ratio
78.47
Revenue / Employee
$500,000
Employees
4
Market Cap
156.93M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.00M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.34M | -1.36M | -50.43% |
| Dec 31, 2022 | 2.70M | -9.00K | -0.33% |
| Dec 31, 2021 | 2.71M | 9.00K | 0.33% |
| Aug 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Spero Therapeutics | 66.80M |
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Fate Therapeutics | 6.65M |
| Humacyte | 2.04M |
| Molecular Partners AG | 856.30K |
| Connect Biopharma Holdings | 64.00K |
ORMP News
- 5 weeks ago - Lifeward Receives Shareholder Approval to Close on Strategic Partnership with Oramed—Creating Diversified Biomedical Company - GlobeNewsWire
- 3 months ago - Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company - GlobeNewsWire
- 3 months ago - Oramed and Lifeward Announce Strategic Transaction - PRNewsWire
- 3 months ago - Oramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments - PRNewsWire
- 5 months ago - Oramed Reports Fiscal Third Quarter 2025 Financial Results - PRNewsWire
- 5 months ago - ORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS - PRNewsWire
- 6 months ago - Oramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Appreciation, and Upcoming Growth Initiatives - PRNewsWire
- 1 year ago - Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical - PRNewsWire